

Monoclonal Antibody to CD262 / TRAILR2 - PE

Alternate names:	DR5, Death receptor 5, KILLER, TNF-related apoptosis-inducing ligand receptor 2, TNFRSF10B, TRAIL receptor 2, TRAIL-R2, TRICK2, Tumor necrosis factor receptor superfamily member 10B, ZTNFR9
Catalog No.:	AM03099RP-N
Quantity:	0.1 mg
Concentration:	0.1 mg/ml
Background:	<p>TRAIL-R2 (CD262, DR5) is one of two TNF superfamily member intracellular death domain containing receptors for TRAIL (APO2L).</p> <p>Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including tumor necrosis factor (TNF) and Fas ligand in the TNF family through their death domain containing receptors, TNF receptor 1 (TNFR1) and Fas, respectively. Another member in the TNF family has been identified and designated TRAIL (for TNF related apoptosis inducing ligand) and Apo2L (for Apo2 ligand). Receptors for TRAIL include two death domain containing receptors, DR4 and DR5, as well as two decoy receptors, DcR1 and DcR2, lacking the intracellular signaling death domain. DcR1 (also called TRID), like the related death receptors DR4 and DR5, contains two extracellular cysteine rich domains. However, DcR1 contains no intracellular death domain and is thus incapable of signaling apoptosis. It has been suggested DcR1 is responsible for TRAIL resistance in normal human tissues including heart, placenta, lung, liver, kidney, spleen, and bone marrow. DR5 is a member of the TNF receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor related apoptosis inducing ligand (TNFSF10/TRAIL/APO2L), and transduces apoptosis signal. Studies with FADD deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.</p>
Uniprot ID:	014763
NCBI:	NP_003833.4
GeneID:	8795
Host / Isotype:	Mouse / IgG1
Clone:	DR5-01-1
Immunogen:	Recombinant fusion protein of human IgG heavy chain and extracellular domain of DR5.
Format:	<p>State: Liquid purified IgG fraction.</p> <p>Purification: Size-Exclusion Chromatography.</p> <p>Buffer System: PBS containing 15 mM Sodium Azide as preservative and 0.2% (w/v) high-grade BSA (Protease free) as stabilizer.</p> <p>Label: PE – Conjugated with R-Phycoerythrin under optimum conditions</p>

For research and in vitro use only. Not for diagnostic or therapeutic work.

Material Safety Datasheets are available at www.acris-antibodies.com or on request.

Antibody Hotline - Technical Questions - Antibody Location Service
Free Call: 0800-2274746 (Germany only) - www.acris-antibodies.com



- Applications:** **Flow Cytometry:** 5 µg/ml.
Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
- Specificity:** The antibody DR5-01-1 recognizes an extracellular domain of TRAIL-R2 (DR5). TRAIL-R2 is one of two TNF superfamily member intracellular death domain containing receptors for TRAIL (APO2L).
- Species Reactivity:** **Tested:** Human.
- Storage:** Store the antibody undiluted in the dark at 2-8°C.
DO NOT FREEZE!
Avoid prolonged exposure to light.
Shelf life: one year from despatch.
- General Readings:** 1. Corallini F, Milani D, Nicolin V, Secchiero P. TRAIL, caspases and maturation of normal and leukemic myeloid precursors. Leuk Lymphoma. 2006 Aug;47(8):1459-68. PubMed PMID: 16966254.

For research and in vitro use only. Not for diagnostic or therapeutic work.

Material Safety Datasheets are available at www.acris-antibodies.com or on request.

Antibody Hotline - Technical Questions - Antibody Location Service
Free Call: 0800-2274746 (Germany only) - www.acris-antibodies.com